Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy.

The connection between weight loss medications and addiction reduction represents a potentially transformative discovery in ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

After a stellar FY24 performance, Natco Pharma’s stock has taken a hit. What’s next for the company as it faces crucial ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...

A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk’s Wegovy. Eli ...